INmune Bio, Inc. (NASDAQ:INMB - Get Free Report) has earned a consensus rating of "Buy" from the six analysts that are presently covering the company, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $22.80.
INMB has been the topic of a number of research reports. Scotiabank upped their target price on INmune Bio from $22.00 to $23.00 and gave the stock a "sector outperform" rating in a research report on Tuesday, February 11th. Maxim Group increased their price target on INmune Bio from $22.00 to $30.00 and gave the company a "buy" rating in a research report on Thursday. Rodman & Renshaw assumed coverage on INmune Bio in a research report on Tuesday, January 28th. They issued a "buy" rating and a $23.00 price target for the company. Alliance Global Partners assumed coverage on INmune Bio in a research report on Monday, October 21st. They set a "buy" rating and a $20.00 target price for the company. Finally, RODMAN&RENSHAW raised INmune Bio to a "strong-buy" rating in a research report on Tuesday, January 28th.
Get Our Latest Report on INMB
INmune Bio Price Performance
Shares of NASDAQ:INMB traded down $0.12 during trading on Thursday, reaching $9.18. 311,175 shares of the stock were exchanged, compared to its average volume of 514,959. INmune Bio has a 1-year low of $4.32 and a 1-year high of $14.49. The stock has a fifty day moving average of $6.69 and a two-hundred day moving average of $6.11. The firm has a market cap of $203.52 million, a price-to-earnings ratio of -4.21 and a beta of 1.87.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in INMB. Wells Fargo & Company MN boosted its stake in INmune Bio by 51.0% in the 4th quarter. Wells Fargo & Company MN now owns 6,377 shares of the company's stock worth $30,000 after purchasing an additional 2,155 shares during the period. Beacon Pointe Advisors LLC purchased a new position in shares of INmune Bio during the 4th quarter valued at about $48,000. JPMorgan Chase & Co. raised its holdings in shares of INmune Bio by 93.0% during the 4th quarter. JPMorgan Chase & Co. now owns 11,335 shares of the company's stock valued at $53,000 after buying an additional 5,461 shares in the last quarter. Two Sigma Advisers LP purchased a new position in shares of INmune Bio during the 4th quarter valued at about $59,000. Finally, Mariner LLC purchased a new position in INmune Bio in the 4th quarter worth approximately $65,000. Institutional investors own 12.72% of the company's stock.
INmune Bio Company Profile
(
Get Free ReportINmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Further Reading
Before you consider INmune Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and INmune Bio wasn't on the list.
While INmune Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
